DC
ROIV icon

Davenport & Co’s Roivant Sciences ROIV Stock Holding History

Davenport & Co’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$481K Buy
13,600
+3,000
+28% +$88.7K ﹤0.01% 1024
2026
Q1 		$294K Buy
+10,600
New +$272K ﹤0.01% 1139
2025
Q4 		– Sell
-10,000
Closed -$151K – 1294
2025
Q3 		$151K Sell
10,000
-2,100
-17% -$26K ﹤0.01% 1205
2025
Q2 		$136K Sell
12,100
-9,600
-44% -$104K ﹤0.01% 1188
2025
Q1 		$219K Sell
21,700
-138,440
-86% -$1.5M ﹤0.01% 1107
2024
Q4 		$1.89M Sell
160,140
-101,300
-39% -$1.2M 0.01% 492
2024
Q3 		$3.02M Sell
261,440
-30,860
-11% -$351K 0.02% 383
2024
Q2 		$3.09M Sell
292,300
-14,400
-5% -$158K 0.02% 368
2024
Q1 		$3.23M Buy
306,700
+23,620
+8% +$255K 0.02% 362
2023
Q4 		$3.18M Buy
283,080
+5,100
+2% +$49.7K 0.02% 336
2023
Q3 		$3.25M Buy
277,980
+23,400
+9% +$265K 0.02% 304
2023
Q2 		$2.57M Buy
254,580
+47,480
+23% +$425K 0.02% 352
2023
Q1 		$1.53M Buy
+207,100
New +$1.71M 0.01% 427

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Davenport & Co's ROIV Position: Q2 2026 in Review

Davenport & Co increased its Roivant Sciences (ROIV) stake by 28% in Q2 2026, buying an estimated $88.7K and bringing the position to 13,600 shares worth $481K. The position accounts for ﹤0.01% of the portfolio, ranked #1024.

Davenport & Co first reported a position in ROIV in Q1 2023 and has held it in 13 quarters since. The position peaked at $3.25M in Q3 2023. 498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Davenport & Co held 13,600 shares of Roivant Sciences worth $481K as of Q2 2026.
  • Davenport & Co bought 3,000 Roivant Sciences shares in Q2 2026, an estimated $88.7K.
  • Roivant Sciences made up ﹤0.01% of Davenport & Co's portfolio in Q2 2026, its #1024 holding.
  • Davenport & Co first reported a position in Roivant Sciences in Q1 2023 and has held it in 13 quarters since.
  • Davenport & Co's Roivant Sciences position peaked at $3.25M in Q3 2023.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Davenport & Co's 13F filing for Q2 2026, filed 13 Jul 2026.